Accelerate Diagnostics Stock Price, News & Analysis (NASDAQ:AXDX)

$27.80 0.45 (1.65 %)
(As of 01/16/2018 10:43 AM ET)
Previous Close$27.35
Today's Range$27.50 - $28.50
52-Week Range$16.75 - $30.45
Volume49,593 shs
Average Volume255,278 shs
Market Capitalization$1.54 billion
P/E Ratio-23.17
Dividend YieldN/A
Beta2.18

About Accelerate Diagnostics (NASDAQ:AXDX)

Accelerate Diagnostics logoAccelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

Receive AXDX News and Ratings via Email

Sign-up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:AXDX
CUSIPN/A
Phone+1-303-8638088

Debt

Debt-to-Equity RatioN/A
Current Ratio21.24%
Quick Ratio20.06%

Price-To-Earnings

Trailing P/E Ratio-23.1666666666667
Forward P/E Ratio-22.79
P/E GrowthN/A

Sales & Book Value

Annual Sales$250,000.00
Price / Sales6,160.48
Cash FlowN/A
Price / CashN/A
Book Value$1.51 per share
Price / Book18.41

Profitability

Trailing EPS($1.20)
Net Income$-66,370,000.00
Net Margins-3,085.36%
Return on Equity-60.99%
Return on Assets-57.85%

Miscellaneous

EmployeesN/A
Outstanding Shares55,400,000

Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics Inc (NASDAQ:AXDX) announced its quarterly earnings data on Thursday, November, 2nd. The medical research company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.32) by $0.01. Accelerate Diagnostics had a negative net margin of 3,085.36% and a negative return on equity of 60.99%. View Accelerate Diagnostics' Earnings History.

Where is Accelerate Diagnostics' stock going? Where will Accelerate Diagnostics' stock price be in 2018?

2 Wall Street analysts have issued 1 year price objectives for Accelerate Diagnostics' shares. Their predictions range from $32.00 to $34.00. On average, they expect Accelerate Diagnostics' stock price to reach $33.00 in the next year. View Analyst Ratings for Accelerate Diagnostics.

Are investors shorting Accelerate Diagnostics?

Accelerate Diagnostics saw a decrease in short interest during the month of November. As of November 30th, there was short interest totalling 10,965,841 shares, a decrease of 8.6% from the November 15th total of 11,995,079 shares. Based on an average daily volume of 818,172 shares, the days-to-cover ratio is presently 13.4 days. Approximately 34.4% of the shares of the stock are short sold.

Who are some of Accelerate Diagnostics' key competitors?

Who are Accelerate Diagnostics' key executives?

Accelerate Diagnostics' management team includes the folowing people:

  • John Patience, Independent Chairman of the Board (Age 69)
  • Lawrence Mehren, President, Chief Executive Officer, Director (Age 50)
  • Steve Reichling, Chief Financial Officer (Age 38)
  • Joan Martin, Executive Vice President & Head of Europe, Middle East, and Africa (Age 48)
  • Ron Price, Senior Vice President and Head of Commercial Operations, Americas (Age 53)
  • Charles Watts, Director
  • Tom Brown, Independent Director (Age 68)
  • Mark C. Miller, Independent Director (Age 61)
  • Jack W. Schuler, Independent Director (Age 76)
  • Matthew W. Strobeck Ph.D., Independent Director (Age 44)

How do I buy Accelerate Diagnostics stock?

Shares of Accelerate Diagnostics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Accelerate Diagnostics' stock price today?

One share of Accelerate Diagnostics stock can currently be purchased for approximately $27.35.

How big of a company is Accelerate Diagnostics?

Accelerate Diagnostics has a market capitalization of $1.54 billion and generates $250,000.00 in revenue each year. The medical research company earns $-66,370,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.

How can I contact Accelerate Diagnostics?

Accelerate Diagnostics' mailing address is 3950 S. Country Club Road #470 Building 3-307, TUCSON, AZ 85714-2240, United States. The medical research company can be reached via phone at +1-303-8638088 or via email at [email protected]


MarketBeat Community Rating for Accelerate Diagnostics (AXDX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  126 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  239
MarketBeat's community ratings are surveys of what our community members think about Accelerate Diagnostics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Accelerate Diagnostics (NASDAQ:AXDX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.503.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $33.00$33.00$33.00$30.33
Price Target Upside: 10.00% upside10.00% upside17.65% upside8.14% upside

Accelerate Diagnostics (NASDAQ:AXDX) Consensus Price Target History

Price Target History for Accelerate Diagnostics (NASDAQ:AXDX)

Accelerate Diagnostics (NASDAQ:AXDX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/13/2017BTIG ResearchDowngradeBuy -> NeutralHighView Rating Details
6/5/2017Piper Jaffray CompaniesReiterated RatingOverweight$30.00 -> $32.00LowView Rating Details
8/9/2016JPMorgan Chase & Co.Boost Price TargetOverweight$17.00 -> $25.00N/AView Rating Details
1/29/2016William BlairReiterated RatingBuyN/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Accelerate Diagnostics (NASDAQ:AXDX) Earnings History and Estimates Chart

Earnings by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Accelerate Diagnostics (NASDAQ AXDX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017($0.32)($0.31)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.30)($0.31)$1.40 million$0.70 millionViewListenView Earnings Details
5/5/2017Q1($0.34)($0.27)$0.60 million$0.50 millionViewListenView Earnings Details
2/27/2017Q4 2016($0.35)($0.31)$0.24 million$0.04 millionViewListenView Earnings Details
11/9/2016Q3 2016($0.35)($0.34)$0.02 millionViewN/AView Earnings Details
8/8/2016Q2 2016($0.32)($0.35)ViewN/AView Earnings Details
5/10/2016Q1 2016($0.26)($0.29)ViewN/AView Earnings Details
3/9/2016Q4 2015($0.29)ViewN/AView Earnings Details
11/2/2015Q3 2015($0.25)ViewN/AView Earnings Details
7/31/2015Q2 2015($0.27)ViewN/AView Earnings Details
5/7/2015Q1 2015($0.20)ViewN/AView Earnings Details
2/26/2015Q4 2014($0.20)ViewN/AView Earnings Details
11/4/2014Q3 2014($0.20)ViewN/AView Earnings Details
8/1/2014Q2 2014($0.19)ViewN/AView Earnings Details
5/2/2014Q1 2014($0.12)ViewN/AView Earnings Details
3/7/2014Q4 2013($0.13)ViewN/AView Earnings Details
11/8/2013Q3 2013($0.10)ViewN/AView Earnings Details
8/9/2013Q2 2013($0.13)ViewN/AView Earnings Details
5/10/2013Q1 2013($0.09)ViewN/AView Earnings Details
12/14/2012Q4 2012($0.06)ViewN/AView Earnings Details
10/26/2012Q3 2012($0.33)ViewN/AView Earnings Details
6/13/2012Q2 2012($0.03)ViewN/AView Earnings Details
3/15/2012Q1 2012($0.03)ViewN/AView Earnings Details
12/14/2011Q4 2011($0.04)ViewN/AView Earnings Details
10/27/2011Q3 2011($0.03)ViewN/AView Earnings Details
9/17/2010Q3 2010$0.17ViewN/AView Earnings Details
6/16/2008Q2 2008($0.04)ViewN/AView Earnings Details
3/17/2008Q1 2008($0.03)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Accelerate Diagnostics (NASDAQ:AXDX) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.22 EPS
Next Year EPS Consensus Estimate: $-1.25 EPS

Dividends

Dividend History for Accelerate Diagnostics (NASDAQ:AXDX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Accelerate Diagnostics (NASDAQ AXDX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 50.00%
Institutional Ownership Percentage: 47.89%
Insider Trades by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)
Institutional Ownership by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Accelerate Diagnostics (NASDAQ AXDX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/17/2017Jack W SchulerDirectorBuy5,500$22.00$121,000.00View SEC Filing  
11/15/2017Jack W SchulerDirectorBuy20,000$20.00$400,000.00View SEC Filing  
11/13/2017Jack W SchulerDirectorBuy20,000$18.98$379,600.00View SEC Filing  
11/10/2017Jack W SchulerDirectorBuy51,181$18.67$955,549.27View SEC Filing  
11/8/2017Jack W SchulerDirectorBuy50,000$18.46$923,000.00View SEC Filing  
11/6/2017Jack W SchulerDirectorBuy340,964$18.51$6,311,243.6444,670View SEC Filing  
10/18/2017Jack W SchulerDirectorBuy45,000$20.14$906,300.00View SEC Filing  
10/16/2017Jack W SchulerDirectorBuy59,922$20.07$1,202,634.54View SEC Filing  
10/13/2017Jack W SchulerDirectorBuy61,300$19.29$1,182,477.00View SEC Filing  
10/12/2017Jack W SchulerDirectorBuy276,200$19.74$5,452,188.00View SEC Filing  
10/11/2017Jack W SchulerDirectorBuy51,600$20.27$1,045,932.00View SEC Filing  
8/21/2017Jack W SchulerDirectorBuy50,000$21.45$1,072,500.00View SEC Filing  
8/17/2017Lawrence MehrenInsiderSell223,215$22.40$5,000,016.00762,381View SEC Filing  
8/15/2017Jack W SchulerDirectorBuy8,200$21.35$175,070.00View SEC Filing  
8/14/2017Jack W SchulerDirectorBuy23,400$21.35$499,590.00View SEC Filing  
8/11/2017Jack W SchulerDirectorBuy80,000$21.43$1,714,400.00View SEC Filing  
6/21/2017Steven ReichlingInsiderSell30,000$28.90$867,000.0030,700View SEC Filing  
1/9/2017Lawrence MehrenInsiderSell400,068$19.00$7,601,292.00View SEC Filing  
1/9/2017Matthew StrobeckDirectorBuy8,000$19.00$152,000.002,045,560View SEC Filing  
6/30/2016Jack W SchulerDirectorBuy90,147$13.95$1,257,550.65View SEC Filing  
6/14/2016Jack W SchulerDirectorBuy14,033$13.67$191,831.11View SEC Filing  
6/13/2016Jack W SchulerDirectorBuy15,967$13.70$218,747.90View SEC Filing  
6/10/2016Jack W SchulerDirectorBuy88,316$14.69$1,297,362.04View SEC Filing  
6/9/2016Jack W SchulerDirectorBuy101,272$14.14$1,431,986.08View SEC Filing  
5/20/2016Jack W SchulerDirectorBuy4,270$11.04$47,140.80View SEC Filing  
5/17/2016Jack W SchulerDirectorBuy10,000$11.45$114,500.00View SEC Filing  
5/16/2016Jack W SchulerDirectorBuy11,511$11.91$137,096.01View SEC Filing  
5/13/2016Jack W SchulerDirectorBuy20,000$12.45$249,000.00View SEC Filing  
2/9/2016Jack W SchulerDirectorBuy600,000$11.86$7,116,000.00View SEC Filing  
2/8/2016Jack W SchulerDirectorBuy20,000$12.32$246,400.00View SEC Filing  
2/5/2016Jack W SchulerDirectorBuy7,308$12.65$92,446.20View SEC Filing  
2/4/2016Jack W SchulerDirectorBuy10,000$12.98$129,800.00View SEC Filing  
2/3/2016Jack W SchulerDirectorBuy50,100$13.09$655,809.00View SEC Filing  
2/2/2016Jack W SchulerDirectorBuy20,000$13.46$269,200.00View SEC Filing  
1/21/2016Jack W SchulerDirectorBuy10,000$15.02$150,200.00View SEC Filing  
12/10/2015Larry N FeinbergMajor ShareholderBuy117,647$17.00$1,999,999.00173,079View SEC Filing  
11/5/2015Jack W SchulerDirectorBuy11,899$16.81$200,022.19View SEC Filing  
11/4/2015Jack W SchulerDirectorBuy52,837$16.81$888,189.97View SEC Filing  
10/22/2015Jack W SchulerDirectorBuy2,160$15.82$34,171.20View SEC Filing  
9/29/2015Brink Frank Jm TenDirectorBuy9,800$15.24$149,352.009,800View SEC Filing  
8/26/2015Jack W SchulerDirectorBuy10,000$17.81$178,100.00View SEC Filing  
8/25/2015Jack W SchulerDirectorBuy10,000$18.56$185,600.00View SEC Filing  
4/17/2015Jack W SchulerDirectorBuy11,000$21.94$241,340.00View SEC Filing  
3/19/2015Matthew StrobeckDirectorBuy2,000$22.04$44,080.00View SEC Filing  
3/9/2015Jack W SchulerDirectorBuy22,584$17.18$387,993.12View SEC Filing  
1/5/2015Jack W SchulerDirectorBuy18,000$18.93$340,740.00View SEC Filing  
9/22/2014Jack W SchulerDirectorBuy2,588$16.44$42,546.72View SEC Filing  
9/19/2014Jack W SchulerDirectorBuy32,411$16.67$540,291.37View SEC Filing  
8/21/2014Jack W SchulerDirectorBuy2,900$16.79$48,691.00View SEC Filing  
8/5/2014Larry N FeinbergMajor ShareholderBuy11,835$15.92$188,413.20View SEC Filing  
8/5/2014Matthew StrobeckDirectorBuy20,000$16.70$334,000.00View SEC Filing  
8/4/2014Matthew StrobeckDirectorBuy20,000$16.70$334,000.00View SEC Filing  
7/16/2014Larry N FeinbergMajor ShareholderBuy20,000$21.54$430,800.00View SEC Filing  
7/1/2014Jack W SchulerDirectorBuy8,698$25.70$223,538.60View SEC Filing  
6/30/2014Jack W SchulerDirectorBuy10,000$26.09$260,900.00View SEC Filing  
6/30/2014Larry N FeinbergMajor ShareholderBuy20,000$25.72$514,400.00View SEC Filing  
5/12/2014Larry N FeinbergMajor ShareholderBuy297,618$16.80$4,999,982.40View SEC Filing  
2/5/2014Larry N FeinbergMajor ShareholderBuy8,554$24.78$211,968.12View SEC Filing  
1/27/2014Larry N FeinbergMajor ShareholderBuy16,307$13.09$213,458.63View SEC Filing  
12/31/2013Larry N FeinbergMajor ShareholderBuy84,081$12.29$1,033,355.49View SEC Filing  
10/30/2013Larry N FeinbergMajor ShareholderBuy10,000$12.95$129,500.00View SEC Filing  
8/30/2013Larry N FeinbergMajor ShareholderBuy16,001$9.76$156,169.76View SEC Filing  
8/28/2013Larry N FeinbergMajor ShareholderBuy158,445$9.80$1,552,761.00View SEC Filing  
8/16/2013Jack W SchulerDirectorBuy78,494$7.88$618,532.72View SEC Filing  
8/14/2013Jack W SchulerDirectorBuy413,090$8.04$3,321,243.60View SEC Filing  
8/14/2013Larry N FeinbergMajor ShareholderBuy36,814$7.24$266,533.36View SEC Filing  
8/9/2013Larry N FeinbergMajor ShareholderBuy35,168$7.30$256,726.40View SEC Filing  
6/21/2013Larry N FeinbergMajor ShareholderBuy114,250$8.00$914,000.00View SEC Filing  
6/12/2013Larry N FeinbergMajor ShareholderBuy7,175$8.41$60,341.75View SEC Filing  
6/7/2013Larry N FeinbergMajor ShareholderBuy45,508$8.33$379,081.64View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Accelerate Diagnostics (NASDAQ AXDX) News Headlines

Source:
DateHeadline
Accelerate Diagnostics (AXDX) Cut to "Sell" at Zacks Investment ResearchAccelerate Diagnostics (AXDX) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - January 15 at 7:28 PM
Accelerate Diagnostics Inc (AXDX) Expected to Post FY2017 Earnings of ($1.22) Per ShareAccelerate Diagnostics Inc (AXDX) Expected to Post FY2017 Earnings of ($1.22) Per Share
www.americanbankingnews.com - January 15 at 3:02 AM
Accelerate Diagnostics (AXDX) & BIOLASE (BIOL) Financial SurveyAccelerate Diagnostics (AXDX) & BIOLASE (BIOL) Financial Survey
www.americanbankingnews.com - January 13 at 3:32 AM
Accelerate Diagnostics achieves CE-IVD milestone for severe bacterial pneumonia assay, doubles revenue for 2017 in ... - GlobeNewswire (press release)Accelerate Diagnostics achieves CE-IVD milestone for severe bacterial pneumonia assay, doubles revenue for 2017 in ... - GlobeNewswire (press release)
globenewswire.com - January 11 at 3:30 PM
Accelerate Diagnostics (AXDX) Reports Prelim. Q4 Revenue of $2.1M; Achieves CE-IVD Milestone for Severe Bacterial Pneumonia AssayAccelerate Diagnostics (AXDX) Reports Prelim. Q4 Revenue of $2.1M; Achieves CE-IVD Milestone for Severe Bacterial Pneumonia Assay
www.streetinsider.com - January 11 at 9:24 AM
Accelerate Diagnostics achieves CE-IVD milestone for severe bacterial pneumonia assay, doubles revenue for 2017 in Q4Accelerate Diagnostics achieves CE-IVD milestone for severe bacterial pneumonia assay, doubles revenue for 2017 in Q4
finance.yahoo.com - January 10 at 10:50 AM
Accelerate Diagnostics (AXDX) Rating Increased to Hold at Zacks Investment ResearchAccelerate Diagnostics (AXDX) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - January 8 at 6:52 PM
Zacks: Accelerate Diagnostics Inc (AXDX) Given $26.50 Average Price Target by AnalystsZacks: Accelerate Diagnostics Inc (AXDX) Given $26.50 Average Price Target by Analysts
www.americanbankingnews.com - January 8 at 9:40 AM
Stocks To Watch: Accelerate Diagnostics Sees RS Rating Rise To 83Stocks To Watch: Accelerate Diagnostics Sees RS Rating Rise To 83
finance.yahoo.com - January 6 at 8:48 AM
Accelerate Diagnostics to Present at the 36th Annual JP Morgan Healthcare Conference in San Francisco - GlobeNewswire (press release)Accelerate Diagnostics to Present at the 36th Annual JP Morgan Healthcare Conference in San Francisco - GlobeNewswire (press release)
globenewswire.com - January 4 at 3:28 PM
Presbia (LENS) vs. Accelerate Diagnostics (AXDX) Head-To-Head ReviewPresbia (LENS) vs. Accelerate Diagnostics (AXDX) Head-To-Head Review
www.americanbankingnews.com - January 2 at 7:14 PM
Stocks To Watch: Accelerate Diagnostics Sees Relative Strength Rating Jump To 82Stocks To Watch: Accelerate Diagnostics Sees Relative Strength Rating Jump To 82
finance.yahoo.com - December 27 at 1:33 PM
 Accelerate Diagnostics Inc (AXDX) Given Consensus Recommendation of "Buy" by Brokerages Accelerate Diagnostics Inc (AXDX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - December 23 at 5:24 PM
Accelerate Diagnostics, Inc. (AXDX)Accelerate Diagnostics, Inc. (AXDX)
finance.yahoo.com - December 20 at 9:30 AM
Short Interest in Accelerate Diagnostics Inc (AXDX) Declines By 8.6%Short Interest in Accelerate Diagnostics Inc (AXDX) Declines By 8.6%
www.americanbankingnews.com - December 18 at 4:36 PM
BTIG Research Lowers Accelerate Diagnostics (AXDX) to NeutralBTIG Research Lowers Accelerate Diagnostics (AXDX) to Neutral
www.americanbankingnews.com - December 17 at 9:24 AM
Technical Perspectives on TrovaGene, Accelerate Diagnostics, NeoGenomics, and Exact SciencesTechnical Perspectives on TrovaGene, Accelerate Diagnostics, NeoGenomics, and Exact Sciences
www.bizjournals.com - December 14 at 9:41 AM
ETFs with exposure to Accelerate Diagnostics, Inc. : December 12, 2017ETFs with exposure to Accelerate Diagnostics, Inc. : December 12, 2017
finance.yahoo.com - December 12 at 3:28 PM
Accelerate Diagnostics Hits 80-Plus Relative Strength Rating BenchmarkAccelerate Diagnostics Hits 80-Plus Relative Strength Rating Benchmark
finance.yahoo.com - December 8 at 3:28 PM
Zacks: Analysts Set $26.50 Target Price for Accelerate Diagnostics Inc (AXDX)Zacks: Analysts Set $26.50 Target Price for Accelerate Diagnostics Inc (AXDX)
www.americanbankingnews.com - December 6 at 5:30 PM
Stocks With Rising Relative Strength: Accelerate DiagnosticsStocks With Rising Relative Strength: Accelerate Diagnostics
finance.yahoo.com - December 6 at 3:28 PM
Accelerate Diagnostics Meets 80-Plus Relative Strength Rating BenchmarkAccelerate Diagnostics Meets 80-Plus Relative Strength Rating Benchmark
finance.yahoo.com - December 1 at 3:32 PM
ETFs with exposure to Accelerate Diagnostics, Inc. : November 30, 2017ETFs with exposure to Accelerate Diagnostics, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 3:28 PM
First Week Of January 2018 Options Trading For Accelerate Diagnostics (AXDX)First Week Of January 2018 Options Trading For Accelerate Diagnostics (AXDX)
www.thestreet.com - November 21 at 4:49 PM
Zacks: Brokerages Set $29.50 Target Price for Accelerate Diagnostics, Inc. (AXDX)Zacks: Brokerages Set $29.50 Target Price for Accelerate Diagnostics, Inc. (AXDX)
www.americanbankingnews.com - November 21 at 3:16 PM
ETFs with exposure to Accelerate Diagnostics, Inc. : November 20, 2017ETFs with exposure to Accelerate Diagnostics, Inc. : November 20, 2017
finance.yahoo.com - November 20 at 5:32 PM
Accelerate Diagnostics, Inc. (AXDX) Director Buys $121,000.00 in StockAccelerate Diagnostics, Inc. (AXDX) Director Buys $121,000.00 in Stock
www.americanbankingnews.com - November 20 at 4:43 PM
Accelerate Diagnostics (AXDX) Appoints Dr. Charles Watts to BoardAccelerate Diagnostics (AXDX) Appoints Dr. Charles Watts to Board
www.streetinsider.com - November 17 at 3:59 PM
Accelerate Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : AXDX-US : November 17, 2017Accelerate Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : AXDX-US : November 17, 2017
finance.yahoo.com - November 17 at 9:54 AM
Insider Buying: Accelerate Diagnostics, Inc. (AXDX) Director Acquires 20,000 Shares of StockInsider Buying: Accelerate Diagnostics, Inc. (AXDX) Director Acquires 20,000 Shares of Stock
www.americanbankingnews.com - November 16 at 4:48 PM
Accelerate Diagnostics (AXDX) Appoints Dr. Charles Watts to Board - StreetInsider.comAccelerate Diagnostics (AXDX) Appoints Dr. Charles Watts to Board - StreetInsider.com
www.streetinsider.com - November 16 at 4:35 PM
Accelerate Diagnostics Welcomes Dr. Charles Watts to its Board of DirectorsAccelerate Diagnostics Welcomes Dr. Charles Watts to its Board of Directors
finance.yahoo.com - November 16 at 4:35 PM
Accelerate Diagnostics to Present at the 29th Annual Piper Jaffray Healthcare Conference in New York CityAccelerate Diagnostics to Present at the 29th Annual Piper Jaffray Healthcare Conference in New York City
finance.yahoo.com - November 16 at 11:44 AM
Accelerate Diagnostics (AXDX) in Focus: Stock Moves 6.7% HigherAccelerate Diagnostics (AXDX) in Focus: Stock Moves 6.7% Higher
finance.yahoo.com - November 16 at 11:44 AM
Accelerate Diagnostics, Inc. (AXDX) Director Buys $379,600.00 in StockAccelerate Diagnostics, Inc. (AXDX) Director Buys $379,600.00 in Stock
www.americanbankingnews.com - November 15 at 8:22 PM
Accelerate Diagnostics, Inc. (AXDX) Director Buys $955,549.27 in StockAccelerate Diagnostics, Inc. (AXDX) Director Buys $955,549.27 in Stock
www.americanbankingnews.com - November 14 at 4:32 PM
Insider Buying: Accelerate Diagnostics, Inc. (AXDX) Director Buys 50,000 Shares of StockInsider Buying: Accelerate Diagnostics, Inc. (AXDX) Director Buys 50,000 Shares of Stock
www.americanbankingnews.com - November 13 at 4:21 PM
ETFs with exposure to Accelerate Diagnostics, Inc. : November 9, 2017ETFs with exposure to Accelerate Diagnostics, Inc. : November 9, 2017
finance.yahoo.com - November 9 at 5:29 PM
Accelerate Diagnostics, Inc. :AXDX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017Accelerate Diagnostics, Inc. :AXDX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017
finance.yahoo.com - November 8 at 6:39 PM
Accelerate Diagnostics, Inc. (AXDX) Director Jack W. Schuler Buys 340,964 SharesAccelerate Diagnostics, Inc. (AXDX) Director Jack W. Schuler Buys 340,964 Shares
www.americanbankingnews.com - November 8 at 3:30 PM
Should You Buy Accelerate Diagnostics Inc (AXDX)?Should You Buy Accelerate Diagnostics Inc (AXDX)?
finance.yahoo.com - November 7 at 6:16 PM
Zacks Investment Research Lowers Accelerate Diagnostics, Inc. (AXDX) to SellZacks Investment Research Lowers Accelerate Diagnostics, Inc. (AXDX) to Sell
www.americanbankingnews.com - November 7 at 5:44 PM
Accelerate Diagnostics (AXDX) CEO Lawrence Mehren on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaAccelerate Diagnostics' (AXDX) CEO Lawrence Mehren on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 5 at 9:12 PM
Brokerages Expect Accelerate Diagnostics, Inc. (AXDX) to Post ($0.31) EPSBrokerages Expect Accelerate Diagnostics, Inc. (AXDX) to Post ($0.31) EPS
www.americanbankingnews.com - November 5 at 3:48 AM
Edited Transcript of AXDX earnings conference call or presentation 2-Nov-17 8:15pm GMTEdited Transcript of AXDX earnings conference call or presentation 2-Nov-17 8:15pm GMT
finance.yahoo.com - November 3 at 4:44 PM
Accelerate Diagnostics reports 3Q lossAccelerate Diagnostics reports 3Q loss
finance.yahoo.com - November 2 at 9:57 PM
Accelerate Diagnostics, Inc. to Host Earnings CallAccelerate Diagnostics, Inc. to Host Earnings Call
finance.yahoo.com - November 2 at 4:52 PM
Accelerate Diagnostics reports Q3 2017 financial resultsAccelerate Diagnostics reports Q3 2017 financial results
finance.yahoo.com - November 2 at 4:52 PM
Accelerate Diagnostics, Inc. (AXDX) Set to Announce Earnings on TuesdayAccelerate Diagnostics, Inc. (AXDX) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - October 31 at 7:44 AM
ETFs with exposure to Accelerate Diagnostics, Inc. : October 26, 2017ETFs with exposure to Accelerate Diagnostics, Inc. : October 26, 2017
finance.yahoo.com - October 26 at 4:19 PM

SEC Filings

Accelerate Diagnostics (NASDAQ:AXDX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Accelerate Diagnostics (NASDAQ:AXDX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Accelerate Diagnostics (NASDAQ AXDX) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.